Monday, April 16, 2018

New Mexico Medical Cannabis Advisory Board Recommendations Are Forthcoming

For Immediate Release:

Monday, April 15th 2018

New Mexico Medical Cannabis Advisory Board Recommendations Are Forthcoming

Santa Fe, NM - The final decisions regarding the medical cannabis Advisory Board recommendations and report from the November 3rd 2017 meeting are expected any day now. The final decision on all those recommendations by the Advisory Board Doctors rest with Secretary Lynn Gallagher at the Department of Health. The New Mexico Department of Health is expected to publicly announce those final decisions at the next meeting on May 11th 2018.

Doctors on the Department of Health Medical Cannabis Advisory Board issued a number of recommendations for addressing the beneficial use of medical cannabis to the Secretary of Health at the November 2017 meeting, including;
Health Conditions Doctors Recommended To Add into the Medical Cannabis Program (MCP):
  • ADD/ADHD & Tourette's Syndrome -Recommended to add to MCP with 5-0 Vote
  • Degenerative Neurological Disorder / Neuroprotective Applications  -Recommended to add to MCP with 5-0 Vote
  • Eczema / Psoriasis -Recommended to add to MCP with 4-1 Vote
  • Muscular Dystrophy -Recommended to add to MCP with 5-0 Vote
  • Post-Concussion Syndrome & TBI -Recommended to add to MCP with 5-0 Vote
  • All Types Seizures (such as: psychogenic neurological disorders; Motor Disorders / Motor Development Disorders)  -Recommended to add to MCP with 5-0 Vote
  • Substance Abuse Disorder(s)  -Recommended to add to MCP with 5-0 Vote (To Include: Alcohol Use Disorder (AUD), Tobacco Use Disorder, Stimulant Use Disorder, Hallucinogen Use Disorder, and Opioid Use Disorder)
Medical Treatment Doctors Recommended To Add into the Medical Cannabis Program (MCP):
  • Medical Treatment Petition; Pediatric Oncology & Medical Cannabis Use for Antiemetic in State Hospitals -Recommended with 5-0 Vote to send a letter of support to Legislature in 2019 Session for a statutory change to add this treatment into the medical cannabis program; the LECUA Act, 2007.
All The Petitions From The November 3rd, 2017 Meeting Can Be Viewed Online At:

2018 Petition Requesting The Inclusion Of A New Medical Condition:
 Autism Spectrum Disorders

​For the second time now, we are petitioning the Department of Health to add Autism Spectrum Disorders into the New Mexico Medical Cannabis Program, our April 2017 Petition was approved by the Advisory Board by a 3-0 Vote and the Secretary decline to add ASD in the program.

States that are already treating ASD with medical cannabis: Minnesota (effective starting in July 2018), Delaware, Georgia, Pennsylvania, and Oregon (under “Developmental Disorder”) all have approved medical cannabis for autism. Arizona, Louisiana, and Colorado is in the process of currently adding ASD into their medical cannabis program too. The following Petition was provided to the Medical Cannabis Program Office on April 11th 2018: Petition Requesting The Inclusion Of A New Medical Condition: Autism Spectrum Disorders, and it can be viewed here:
The Medical Cannabis Advisory Board Public Meeting will be on Friday, May 11 2018 at 10:00 am to 1:00 pm at the Harold Runnels Building (1190 S. St. Francis Drive, Santa Fe, NM 87505) and the meeting will be on the first floor in the auditorium (Room A-1006). You may obtain the Medical Cannabis Advisory Board Meeting Agenda no later than 72 hours before the meeting from the Department of Health.

About Safe Access New Mexico 
We focus solely on medical cannabis issues, decriminalization of cannabis, hemp policy and do not work on legalization of cannabis for non-medical purposes or other illicit drug issues.

Legalization of Cannabis for Recreational Use
Background: As the national debate heightens around the legalization of cannabis (or marijuana) for recreational use, policy makers, the media, as well as ASA members and affiliates have called on ASA to take a position on these issues. ASA was founded to focus only on medical cannabis issues. Recreational use and medical use have only the criminal justice system in common.
Findings: Issues such as access, police harassment, and the price and quality of medicine will still be relevant to the patient community despite the adoption of a policy of legalization for recreational use. The federal refusal to recognize the medical efficacy of cannabis causes more harm and difficulty for patients than any failure by local or state governments to adopt policies of legalization of cannabis for recreational use. Any system of regulation should not be built on the backs of current medical cannabis laws.
Position:  The legalization of cannabis for recreational use is a separate issue from safe and legal access to cannabis for therapeutic use. We caution policy makers against letting the debate surrounding legalization of cannabis for recreational use obscure the science and policy regarding the medical use of cannabis.

About Americans for Safe Access

The mission of Americans for Safe Access (ASA) is to ensure safe and legal access to cannabis (marijuana) for therapeutic use and research.

ASA was founded in 2002, by medical cannabis patient Steph Sherer, as a vehicle for patients to advocate for the acceptance of cannabis as medicine. With over 100,000 active members in all 50 states, ASA is the largest national member-based organization of patients, medical professionals, scientists and concerned citizens promoting safe and legal access to cannabis for therapeutic use and research. ASA works to overcome political, social and legal barriers by creating policies that improve access to medical cannabis for patients and researchers through legislation, education, litigation, research, grassroots empowerment, advocacy and services for patients, governments, medical professionals, and medical cannabis providers.

Ensuring safe and legal access to cannabis means:
  • International, federal and state laws and regulations recognized cannabis as a legal medicine.
  • Medical professionals recommend medical cannabis options as a frontline treatment option or an adjunct therapy.
  • Patients and their caregivers have the information they need to make educated choices about medical cannabis therapies.
  • Patients and medical professionals can incorporate a diverse group of products and delivery methods to create required personalized treatment regimen.
  • Patients can trust labels on products and that medicines are free of pesticides and contaminants.
  • Medical cannabis treatments are covered by insurance.

Become a part of history! Join us today.

Safe Access New Mexico
LECUA Patients Coalition of New Mexico